TABLE 1.
Confirmed hits for at least two of three concentrations in HCS screen with a library of 1,120 chemical compounds on Huh-7 cells infected with HCVcc JFH1 (genotype 2a)a
| Concentrations | CAS no. | Product name | Description | Reference(s) for described HCV inhibitory mechanism |
|---|---|---|---|---|
| 1, 10, and 20 μM | 35943-35-2 | API-2 | Selective inhibitor of Akt/PKB signaling | 15, 61, 62 |
| 40796-97-2 | MDL 72222 | 5-HT3 antagonist | ||
| 1 and 10 μM | 30484-77-6 | Flunarizine dihydrochloride | Dual Na+/Ca2+ channel (T-type) blocker | 16 |
| 10 and 20 μM | 627536-09-8 | SD 208 | Potent ATP-competitive transforming growth factor beta receptor I (TGF-βRI) inhibitor | 63 |
| 152121-47-6 | SB203580 | Selective inhibitor of p38 mitogen-activated protein kinase (MAPK) | 64, 65 | |
| 152121-30-7 | SB202190 | Potent, selective inhibitor of p38 MAPK | 14, 66 | |
| 869185-85-3 | SB203580 hydrochloride | Selective inhibitor of p38 MAPK | 64, 65 | |
| 129453-61-8 | ICI 182,780 | Estrogen receptor antagonist | 13 | |
| 138356-20-4 | BD 1047 dihydrobromide | σ1 selective antagonist | 12 | |
| 138356-09-9 | BD 1008 dihydrobromide | Potent, selective σ ligand | 12 | |
| 35838-58-5 | Etazolate hydrochloride | PDE4 inhibitor | ||
| 67197-96-0 | (−)-U-50488 hydrochloride | Standard selective κ agonist | ||
| 114528-79-9 | (±)-U-50488 hydrochloride | Standard selective κ agonist | ||
| 207403-36-9 | MR 16728 hydrochloride | Stimulates ACh release | ||
| 155059-42-0 | SM-21 maleate | Presynaptic cholinergic modulator | ||
| 155649-00-6 | PG-9 maleate | Presynaptic cholinergic modulator | ||
| 209480-63-7 | SB258585 hydrochloride | Potent, selective 5-HT6 antagonist | ||
| 66611-27-6 | RU 24969 hemisuccinate | 5-HT1B/1A agonist | ||
| 61718-82-9 | Fluvoxamine maleate | 5-HT reuptake inhibitor | ||
| 59729-32-7 | Citalopram hydrobromide | Highly potent and selective 5-HT uptake inhibitor |
a
CAS numbers of the compounds, as well as their main known targets, are indicated. Compounds described as having an inhibitory effect on HCV or targeting a pathway described to be involved in HCV infection are indicated.